Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer, Glaxo Agree to Create Over-The-Counter Drug Giant--4th Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2018 | 02:54pm EDT

By Denise Roland in London and Jared Hopkins in New York

Pfizer Inc. and GlaxoSmithKline PLC plan to combine their consumer health-care units and eventually spin off the joint venture, creating the world's largest seller of drugstore staples like Advil and Sensodyne toothpaste.

The deal, announced Wednesday, is an unexpected conclusion to a yearlong process by Pfizer to shed its consumer business, as it and other pharmaceutical companies focus on higher-margin prescription drugs. While Glaxo has shared that focus, the British drugmaker had remained committed to its consumer business, which its chief executive led before her promotion to the top job last year.

The planned spinoff would represent a breakup of Glaxo, which currently generates around a quarter of its revenue from consumer products, compared with 7% at Pfizer.

Glaxo will hold a 68% stake and New York-based Pfizer the remaining 32% in the new joint venture, which generated combined sales of $12.7 billion last year. Among its other brands are nicotine-replacement gum Nicorette, heartburn tablets Tums and Centrum multivitamins.

Glaxo said it expects the deal to close in the second half of 2019, with a spinoff of the joint venture happening within three years through a listing on the U.K. stock market.

The new business today could command a market valuation of about $42 billion, according to Mick Cooper, an analyst at Trinity Delta, a research house.

As a stand-alone consumer health-care business, it would be rare. Similar operations typically are part of big pharmaceutical companies, like Sanofi SA and Bayer AG, or consumer-goods giants, like Procter & Gamble Co. and Reckitt Benckiser Group PLC.

Investors welcomed the news, with Glaxo shares rising as much as 7% in London before ending the day up almost 4%. Pfizer was up 0.8% in New York.

The deal will free up both companies to concentrate on prescription medicines, which tend to be more profitable if also higher risk.

Companies have used the steady revenue of over-the-counter drugs to help them smooth out boom-and-bust cycles for blockbuster treatments. For Glaxo, without its consumer health-care business, that role will fall to the vaccines business, which has relatively stable revenue flows. Pfizer also sells vaccines, as well as generic drugs.

"There are benefits to having a broader structure but these are significantly outweighed by the value creation of the deal we are announcing today," Glaxo Chief Executive Emma Walmsley said Wednesday on a call with reporters.

Ms. Walmsley said the increased cash flow from the joint venture would allow her company to invest heavily in its pipeline of new medicines. Melding the two consumer businesses would also allow for cost cuts: Glaxo and Pfizer said they expect savings of GBP500 million ($631.2 million) a year by 2022.

Consumer products used to be integral to many big drug companies, but their businesses have diverged in recent years. Prescription drugs treat deadly, debilitating and rare diseases and require different research, sales and manufacturing capabilities.

Sales of over-the-counter medicines also can't match the growth potential of prescription drugs. For one, big retailers with a strong online presence like Amazon.com Inc. and Walmart Inc. are squeezing margins in what some refer to as "the Amazon effect."

Those same retailers are also increasing competition through store-brand products. Earlier this year Amazon launched some over-the-counter items with Perrigo PLC.

The Glaxo-Pfizer joint venture will expand the global reach of the U.S. company's consumer brands and buttress negotiations with major retailers, said Ashtyn Evans, an analyst at Edwards Jones & Co.

For Pfizer, Wednesday's deal represents a swan song for departing Chief Executive Ian Read, who tried selling the company's consumer division outright but failed after pricing the business too high, according to people familiar with the matter. Under his tenure, Pfizer shed noncore businesses, notably its animal-health business, which is now an independent public company called Zoetis Inc.

Glaxo had been interested in Pfizer's consumer division when it was on the block, but walked away because it didn't want to acquire the business outright, according to Ms. Walmsley. Instead, the U.K. company this year bought Novartis AG's stake in the pair's consumer health-care venture for $13 billion.

Recasting the Pfizer transaction as an all-equity deal was more appealing, Ms. Walmsley said.

Pfizer has been shedding noncore businesses, notably its animal-health business, which is now an independent public company called Zoetis Inc.

Dialing back on consumer health will allow incoming Pfizer CEO Albert Bourla to focus further on ratcheting up prescription-drug sales after the company weathered several years of patent expiries, including that of the cholesterol fighter Lipitor. He takes the helm on Jan. 1.

For Glaxo, the deal is Ms. Walmsley's biggest move yet to reshape the company.

Since becoming CEO in April 2017, Ms. Walmsley has bulked up the prescription-drug business with the $4.16 billion acquisition of cancer drugmaker Tesaro Inc., while shedding Glaxo's nutrition business in a $3.75 billion sale to Unilever PLC.

She has also shaken up the company's top ranks and cut several scientific programs to concentrate on researching drugs that focus on immunology or that have a genetic basis.

Pfizer and Glaxo aren't alone in off-loading slower-growing businesses in favor of prescription-drug pipelines Bristol-Myers Squibb Co. on Wednesday announced the sale of its French consumer-healthcare business Upsa to Japan's Taisho Pharmaceutical Holdings.

Meanwhile, those drugmakers sticking with consumer health care have bulked up to get scale. In recent years, Sanofi bought Boehringer Ingelheim's consumer business and Bayer snapped up Merck & Co.'s over-the-counter medicines.

Write to Denise Roland at Denise.Roland@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 1.32% 17.96 Delayed Quote.8.00%
GLAXOSMITHKLINE 0.79% 1605.6 Delayed Quote.7.67%
PFIZER 0.00% 43.76 Delayed Quote.0.25%
VALUE8 -0.37% 5.46 Delayed Quote.15.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
06/25AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan
RE
06/25AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan
RE
06/25PFIZER : Thinking about trading options or stock in Alibaba, Coupa Software, Ele..
PR
06/25PFIZER : The Conference Forum Announces Disruptive Innovations in Clinical Trial..
AQ
06/25PFIZER : Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA..
AQ
06/24PFIZER INC. : - European Commission Approves TALZENNA for Patients with Inherite..
AQ
06/24SANGAMO THERAPEUTICS : Announces Upcoming Presentation of Investigational SB-525..
AQ
06/24BIOMARIN PHARMACEUTICAL : Earns Milestone Payments from Pfizer for TALZENNA for ..
AQ
06/24PFIZER : European Commission Approves TALZENNA (talazoparib) for Patients with I..
AQ
06/22PFIZER : Manufacturing of paediatric medicines set to improve with new investmen..
AQ
More news
Financials ($)
Sales 2019 53 351 M
EBIT 2019 19 750 M
Net income 2019 13 323 M
Debt 2019 26 335 M
Yield 2019 3,27%
P/E ratio 2019 18,19
P/E ratio 2020 16,61
EV / Sales 2019 5,05x
EV / Sales 2020 4,96x
Capitalization 243 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 45,6 $
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER0.25%233 072
JOHNSON & JOHNSON10.10%348 981
ROCHE HOLDING LTD.13.50%227 848
NOVARTIS21.44%220 893
MERCK AND COMPANY11.91%206 641
ELI LILLY AND COMPANY-0.20%113 364